{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:50:11Z","timestamp":1791561011446,"version":"4.3.4"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41409-026-02991-1","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T12:44:00Z","timestamp":1784292240000},"page":"1343-1352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of conditioning regimen on outcomes of young AML patients (\u2009&lt;\u200940 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation"],"prefix":"10.1038","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7356-2328","authenticated-orcid":false,"given":"Enrico","family":"Maffini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7810-6900","authenticated-orcid":false,"given":"Maud","family":"Ngoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Houhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8444-890X","authenticated-orcid":false,"given":"Malek","family":"Benakli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Bahar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3942-7370","authenticated-orcid":false,"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1161-9138","authenticated-orcid":false,"given":"Khalid","family":"Halahleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regis","family":"Peffault de Latour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor-Wolfgang","family":"Blau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Pal","family":"Remenyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Losa","family":"Maroto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4524-8782","authenticated-orcid":false,"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Sengeloev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7728-5804","authenticated-orcid":false,"given":"Cristina","family":"Castilla-Llorente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6439-0795","authenticated-orcid":false,"given":"Emma","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urpu","family":"Salmenniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3323-3487","authenticated-orcid":false,"given":"Radovan","family":"Vrhovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7092-3351","authenticated-orcid":false,"given":"Jakob","family":"Passweg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3362-5814","authenticated-orcid":false,"given":"Matthias","family":"Eder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Daguindau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-2532","authenticated-orcid":false,"given":"Alexandros","family":"Spyridonidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0763-1265","authenticated-orcid":false,"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0873-0123","authenticated-orcid":false,"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7264-808X","authenticated-orcid":false,"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,17]]},"reference":[{"key":"2991_CR1","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30035-8","volume":"5","author":"C Craddock","year":"2018","unstructured":"Craddock C. Conditioning intensity in HCT for AML: the jury is still out. Lancet Haematol. 2018;5:e132\u2013e133.","journal-title":"Lancet Haematol"},{"key":"2991_CR2","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1111\/bjh.70170","volume":"207","author":"R Alyamany","year":"2025","unstructured":"Alyamany R, Alnughmush A, Remberger M, Datt Law A, Lam W, Hwan Kim DD, et al. Can we move beyond myeloablative conditioning (MAC)? A comparison of MAC versus reduced intensity conditioning (RIC) in patients aged younger than 65\u2009years undergoing allogeneic haematopoietic cell transplantation using ATG-PTCy-CSA for GVHD prophylaxis. Br J Haematol. 2025;207:2507\u201316.","journal-title":"Br J Haematol"},{"key":"2991_CR3","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1002\/ajh.25211","volume":"93","author":"MH Gilleece","year":"2018","unstructured":"Gilleece MH, Labopin M, Yakoub-Agha I, Volin L, Soci\u00e9 G, Ljungman P, et al. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation. Am J Hematol. 2018;93:1142\u201352.","journal-title":"Am J Hematol"},{"key":"2991_CR4","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1200\/JCO.22.00767","volume":"41","author":"H Zhang","year":"2023","unstructured":"Zhang H, Fan Z, Huang F, Han L, Xu Y, Xu N, et al. Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III Trial. J Clin Oncol. 2023;41:343\u201353.","journal-title":"J Clin Oncol"},{"key":"2991_CR5","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1182\/blood-2013-08-519009","volume":"122","author":"C Bredeson","year":"2013","unstructured":"Bredeson C, LeRademacher J, Kato K, DiPersio JF, Agura E, Devine SM, et al. Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood. 2013;122:3871\u20138.","journal-title":"Blood"},{"key":"2991_CR6","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1016\/0360-3016(83)90365-6","volume":"9","author":"HJ Deeg","year":"1983","unstructured":"Deeg HJ. Acute and delayed toxicities of total body irradiation. Seattle Marrow Transplant Team. Int J Radiat Oncol Biol Phys. 1983;9:1933\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2991_CR7","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1182\/blood.2018874115","volume":"133","author":"KS Baker","year":"2019","unstructured":"Baker KS, Leisenring WM, Goodman PJ, Ermoian RP, Flowers ME, Schoch G, et al. Total body irradiation dose and risk of subsequent neoplasms following allogeneic hematopoietic cell transplantation. Blood. 2019;133:2790\u20139.","journal-title":"Blood"},{"key":"2991_CR8","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","volume":"16","author":"A Rambaldi","year":"2015","unstructured":"Rambaldi A, Grassi A, Masciulli A, Boschini C, Mic\u00f2 MC, Busca A, et al. Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2015;16:1525\u201336.","journal-title":"Lancet Oncol"},{"key":"2991_CR9","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1200\/JCO.2011.40.2362","volume":"31","author":"J-H Lee","year":"2013","unstructured":"Lee J-H, Joo Y-D, Kim H, Ryoo HM, Kim MK, Lee G-W, et al. Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine. J Clin Oncol. 2013;31:701\u20139.","journal-title":"J Clin Oncol"},{"key":"2991_CR10","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/bmt.2012.13","volume":"47","author":"J Sanz","year":"2012","unstructured":"Sanz J, Boluda JCH, Martin C, Gonzalez M, Ferr\u00e0 C, Serrano D, et al. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transpl. 2012;47:1287\u201393.","journal-title":"Bone Marrow Transpl"},{"key":"2991_CR11","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3324\/haematol.2020.268839","volume":"106","author":"N Gagelmann","year":"2021","unstructured":"Gagelmann N, Kr\u00f6ger N. Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend \u2018when and for whom\u2019 in 2021? Haematologica. 2021;106:1794\u2013804.","journal-title":"Haematologica"},{"key":"2991_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41409-023-02139-5","volume":"59","author":"A Spyridonidis","year":"2024","unstructured":"Spyridonidis A, Labopin M, Gedde-Dahl T, Ganser A, Stelljes M, Craddock C, et al. Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantation. Bone Marrow Transpl. 2024;59:217\u201323.","journal-title":"Bone Marrow Transpl"},{"key":"2991_CR13","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2991_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2991\/chi.d.191207.001","volume":"2","author":"AS Kanate","year":"2020","unstructured":"Kanate AS, Nagler A, Savani B. Summary of Scientific and Statistical Methods, Study Endpoints and Definitions for Observational and Registry-Based Studies in Hematopoietic Cell Transplantation. Clin Hematol Int. 2020;2:2\u20134.","journal-title":"Clin Hematol Int"},{"key":"2991_CR15","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transpl. 1995;15:825\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2991_CR16","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","volume":"11","author":"AH Filipovich","year":"2005","unstructured":"Filipovich AH, Weisdorf D, Pavletic S, Soci\u00e9 G, Wingard JR, Lee SJ, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transpl. 2005;11:945\u201356.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2991_CR17","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/bmt.2015.305","volume":"51","author":"A Ruggeri","year":"2016","unstructured":"Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP\u2013EBMT analysis on patients with AML in remission. Bone Marrow Transpl. 2016;51:610\u20131.","journal-title":"Bone Marrow Transpl"},{"key":"2991_CR18","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","volume":"55","author":"A Spyridonidis","year":"2020","unstructured":"Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transpl. 2020;55:1114\u201325.","journal-title":"Bone Marrow Transpl"},{"key":"2991_CR19","doi-asserted-by":"publisher","first-page":"e356","DOI":"10.1016\/j.bbmt.2019.08.005","volume":"25","author":"R Storb","year":"2019","unstructured":"Storb R, Georges GE, Gooley TA. Total Body Irradiation\u2013Based versus Chemotherapy-Based Myeloablative Conditioning for Allogeneic Hematopoietic Cell Transplant. Biol Blood Marrow Transpl. 2019;25:e356\u2013e362.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2991_CR20","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1182\/blood.V94.11.3960a","volume":"94","author":"RA Clift","year":"1999","unstructured":"Clift RA, Radich J, Appelbaum FR, Martin P, Flowers ME, Deeg HJ, et al. Long-term follow-up of a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide for patients receiving allogenic marrow transplants during chronic phase of chronic myeloid leukemia. Blood. 1999;94:3960\u20132.","journal-title":"Blood"},{"key":"2991_CR21","first-page":"S148","volume":"32","author":"N Amirmokhtari","year":"2026","unstructured":"Amirmokhtari N, Fahmawi S, Rukh S, Kashif Amin M, Umair Mushtaq M. Lufti F. Long Term Effects of TBI Based Versus Non-TBI Based Myeloablative Conditioning in AYA AML Patients, a Systematic Review. Transpl Cell Ther. 2026;32:S148\u2013S149.","journal-title":"Transpl Cell Ther"},{"key":"2991_CR22","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.bbmt.2016.11.022","volume":"23","author":"G Lucchini","year":"2017","unstructured":"Lucchini G, Labopin M, Beohou E, Dalissier A, Dalle JH, Cornish J, et al. Impact of Conditioning Regimen on Outcomes for Children with Acute Myeloid Leukemia Undergoing Transplantation in First Complete Remission. An Analysis on Behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2017;23:467\u201374.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2991_CR23","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3324\/haematol.2020.249458","volume":"106","author":"CE Dandoy","year":"2021","unstructured":"Dandoy CE, Davies SM, Ahn KW, He Y, Kolb AE, Levine J, et al. Comparison of total body irradiation versus non-total body irradiation containing regimens for de novo acute myeloid leukemia in children. Haematologica. 2021;106:1839\u201345.","journal-title":"Haematologica"},{"key":"2991_CR24","first-page":"530","volume":"28","author":"K Tarlock","year":"2022","unstructured":"Tarlock K, Sulis ML, Chewning JH, Pollard JA, Cooper T, Gamis A, et al. Hematopoietic Cell Transplantation in the Treatment of Pediatric Acute Myelogenous Leukemia and Myelodysplastic Syndromes: Guidelines from the American Society of Transplantation and Cellular Therapy. Transpl Cell Ther. 2022;28:530\u201345.","journal-title":"Transpl Cell Ther"},{"key":"2991_CR25","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1182\/blood-2013-07-514448","volume":"122","author":"EA Copelan","year":"2013","unstructured":"Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, et al. Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood. 2013;122:3863\u201370.","journal-title":"Blood"},{"key":"2991_CR26","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1002\/cncr.28768","volume":"120","author":"S Giebel","year":"2014","unstructured":"Giebel S, Miszczyk L, Slosarek K, Moukhtari L, Ciceri F, Esteve J, et al. Extreme heterogeneity of myeloablative total body irradiation techniques in clinical practice: A survey of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Cancer. 2014;120:2760\u20135.","journal-title":"Cancer"},{"key":"2991_CR27","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ijrobp.2018.06.015","volume":"102","author":"Y Belkacemi","year":"2018","unstructured":"Belkacemi Y, Labopin M, Giebel S, Loganadane G, Miszczyk L, Michallet M, et al. Single-Dose Daily Fractionation Is Not Inferior to Twice-a-Day Fractionated Total-Body Irradiation Before Allogeneic Stem Cell Transplantation for Acute Leukemia: A Useful Practice Simplification Resulting From the SARASIN Study. Int J Radiat Oncol Biol Phys. 2018;102:515\u201326.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2991_CR28","first-page":"185.e1","volume":"27","author":"N Ueda","year":"2021","unstructured":"Ueda N, Konuma T, Aoki J, Takahashi S, Ozawa Y, Mori T, et al. Prognostic Impact of the Fractionation of Total Body Irradiation for Patients with Acute Myeloid Leukemia Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. Transpl Cell Ther. 2021;27:185.e1\u2013185.e6.","journal-title":"Transpl Cell Ther"},{"key":"2991_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01116-5","volume":"14","author":"G Cavallaro","year":"2024","unstructured":"Cavallaro G, Grassi A, Pavoni C, Mic\u00f2 MC, Busca A, Cavattoni IM, et al. Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trial. Blood Cancer J. 2024;14:141.","journal-title":"Blood Cancer J"},{"key":"2991_CR30","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1200\/JCO.23.00101","volume":"41","author":"Y Ling","year":"2023","unstructured":"Ling Y, Xuan L, Xu N, Huang F, Fan Z, Guo Z, et al. Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial. J Clin Oncol. 2023;41:4632\u201342.","journal-title":"J Clin Oncol"},{"key":"2991_CR31","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1038\/s41409-022-01830-3","volume":"57","author":"E Gavriilaki","year":"2022","unstructured":"Gavriilaki E, Labopin M, Sakellari I, Salmenniemi U, Yakoub-Agha I, Potter V, et al. Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP). Bone Marrow Transpl. 2022;57:1803\u20139.","journal-title":"Bone Marrow Transpl"},{"key":"2991_CR32","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41409-022-01882-5","volume":"58","author":"R Swoboda","year":"2023","unstructured":"Swoboda R, Labopin M, Giebel S, Schroeder T, Kroger N, Arat M, et al. Total body irradiation plus fludarabine versus busulfan plus fludarabine as a myeloablative conditioning for adults with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation. A study on behalf of the Acute Leukemia Working Party of the EBMT. Bone Marrow Transpl. 2023;58:282\u20137.","journal-title":"Bone Marrow Transpl"},{"key":"2991_CR33","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/j.bbmt.2019.02.025","volume":"25","author":"R Dul\u00e9ry","year":"2019","unstructured":"Dul\u00e9ry R, Bastos J, Paviglianiti A, Malard F, Brissot E, Battipaglia G, et al. Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transpl. 2019;25:1407\u201315.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2991_CR34","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1002\/ajh.25225","volume":"93","author":"F Saraceni","year":"2018","unstructured":"Saraceni F, Beohou E, Labopin M, Arcese W, Bonifazi F, Stepensky P, et al. Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. Am J Hematol. 2018;93:1211\u20139.","journal-title":"Am J Hematol"},{"key":"2991_CR35","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-018-0655-8","volume":"11","author":"F Giannotti","year":"2018","unstructured":"Giannotti F, Labopin M, Shouval R, Sanz J, Arcese W, Angelucci E, et al. Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine. J Hematol Oncol. 2018;11:110.","journal-title":"J Hematol Oncol"},{"key":"2991_CR36","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.clml.2020.01.007","volume":"20","author":"J El-Cheikh","year":"2020","unstructured":"El-Cheikh J, Labopin M, Al-Chami F, Bazarbachi A, Angelucci E, Santarone S, et al. Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party. Clin Lymphoma Myeloma Leuk. 2020;20:296\u2013304.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2991_CR37","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1016\/j.bbmt.2019.12.725","volume":"26","author":"F Sora","year":"2020","unstructured":"Sora F, Di Grazia C, Chiusolo P, Raiola AM, Bregante S, Mordini N, et al. Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study. Biol Blood Marrow Transpl. 2020;26:698\u2013703.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2991_CR38","doi-asserted-by":"publisher","first-page":"e952","DOI":"10.1097\/HS9.0000000000000952","volume":"7","author":"F Saraceni","year":"2023","unstructured":"Saraceni F, Labopin M, Raiola AM, Blaise D, Rem\u00e9nyi P, Sor\u00e0 F, et al. Thiotepa-busulfan-fludarabine Compared to Treosulfan-based Conditioning for Haploidentical Transplant With Posttransplant Cyclophosphamide in Patients With Acute Myeloid Leukemia in Remission: A Study From the Acute Leukemia Working Party of the EBMT. HemaSphere. 2023;7:e952.","journal-title":"HemaSphere"},{"key":"2991_CR39","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1182\/blood-2025-110","volume":"146","author":"C Craddock","year":"2025","unstructured":"Craddock C, Mcllroy G, Vincent H, Smith G, Johnson S, Collings R, et al. Addition of thiotepa to a busulphan based conditioning regimen does not improve survival in patients allografted for acute myeloid leukaemia and myelodysplasia: Results of the UK impact cosi trial. Blood. 2025;146:110.","journal-title":"Blood"},{"key":"2991_CR40","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/s41409-024-02197-3","volume":"59","author":"A Sharma","year":"2024","unstructured":"Sharma A, Galimard J-E, Pryce A, Bhoopalan SV, Dalissier A, Dalle J-H, et al. Cytogenetic abnormalities predict survival after allogeneic hematopoietic stem cell transplantation for pediatric acute myeloid leukemia: a PDWP\/EBMT study. Bone Marrow Transpl. 2024;59:451\u20138.","journal-title":"Bone Marrow Transpl"},{"key":"2991_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00953-0","volume":"13","author":"M Mozaffari Jovein","year":"2023","unstructured":"Mozaffari Jovein M, Ihorst G, Duque-Afonso J, W\u00e4sch R, Bertz H, Wehr C, et al. Long-term follow-up of patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation after primary induction failure. Blood Cancer J. 2023;13:179.","journal-title":"Blood Cancer J"},{"key":"2991_CR42","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/s41409-023-01953-1","volume":"58","author":"MA de Witte","year":"2023","unstructured":"de Witte MA, Mooyaart JE, Hoogenboom JD, Chabannon C, Malard F, Ruggeri A, et al. Activity of ex vivo graft and DLI Engineering within the last decade increases, a survey from the EBMT Cellular Therapy & Immunobiology Working Party. Bone Marrow Transpl. 2023;58:719\u201322.","journal-title":"Bone Marrow Transpl"},{"key":"2991_CR43","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.3324\/haematol.2024.287177","volume":"110","author":"P Smallbone","year":"2025","unstructured":"Smallbone P, Shigle TL, Paslovsky O, Hosing C, Alousi A, Bashir Q, et al. Maintenance therapy with oral decitabine plus cedazuridine after allogeneic stem cell transplantation for myelodysplastic syndrome. Haematologica. 2025;110:1798\u2013807.","journal-title":"Haematologica"},{"key":"2991_CR44","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1182\/bloodadvances.2022008632","volume":"6","author":"AT Fathi","year":"2022","unstructured":"Fathi AT, Kim HT, Soiffer RJ, Levis MJ, Li S, Kim AS, et al. Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies. Blood Adv. 2022;6:5857\u201365.","journal-title":"Blood Adv"},{"key":"2991_CR45","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1182\/bloodadvances.2023012120","volume":"8","author":"JS Garcia","year":"2024","unstructured":"Garcia JS, Kim HT, Murdock HM, Ansuinelli M, Brock J, Cutler CS, et al. Prophylactic maintenance with venetoclax\/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. Blood Adv. 2024;8:978\u201390.","journal-title":"Blood Adv"},{"key":"2991_CR46","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1001\/jamaoncol.2021.3676","volume":"7","author":"S Bhatia","year":"2021","unstructured":"Bhatia S, Dai C, Landier W, Hageman L, Wu J, Schlichting E, et al. Trends in Late Mortality and Life Expectancy After Allogeneic Blood or Marrow Transplantation Over 4 Decades: A Blood or Marrow Transplant Survivor Study Report. JAMA Oncol. 2021;7:1626\u201334.","journal-title":"JAMA Oncol"},{"key":"2991_CR47","doi-asserted-by":"crossref","unstructured":"Cibich A, Wechalekar G, Shanmuganathan N, Singhal D, Beligaswatte A, Wayte R, et al. Long-Term Survival Gains after Allogeneic Hematopoietic Stem Cell Transplant are Driven by Reductions in Non-Relapse Mortality: A 35-Year Statewide Australian Cohort Study. Transpl Cell Ther. 2026; 32:689.e1\u2013689.e13.","DOI":"10.1016\/j.jtct.2026.01.024"},{"key":"2991_CR48","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1007\/s12185-022-03426-5","volume":"116","author":"Y Ishida","year":"2022","unstructured":"Ishida Y, Kamibeppu K, Sato A, Inoue M, Hayakawa A, Shiobara M, et al. Karnofsky performance status and visual analogue scale scores are simple indicators for quality of life in long-term AYA survivors who received allogeneic hematopoietic stem cells transplantation in childhood. Int J Hematol. 2022;116:787\u201397.","journal-title":"Int J Hematol"},{"key":"2991_CR49","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3389\/fimmu.2017.00496","volume":"8","author":"AM Dickinson","year":"2017","unstructured":"Dickinson AM, Norden J, Li S, Hromadnikova I, Schmid C, Schmetzer H, et al. Graft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia. Front Immunol. 2017;8:496.","journal-title":"Front Immunol"},{"key":"2991_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.17.00078","volume":"21","author":"J Versluis","year":"2017","unstructured":"Versluis J, Kalin B, Zeijlemaker W, Passweg J, Graux C, Manz MG, et al. Graft-Versus-Leukemia Effect of Allogeneic Stem-Cell Transplantation and Minimal Residual Disease in Patients With Acute Myeloid Leukemia in First Complete Remission. JCO Precis Oncol. 2017;21:1\u201313.","journal-title":"JCO Precis Oncol"},{"key":"2991_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70026","volume":"8","author":"M Larue","year":"2024","unstructured":"Larue M, Labopin M, Schroeder T, Huang X-J, Blau IW, Schetelig J, et al. Long-term outcome of 2-year survivors after allogeneic hematopoietic cell transplantation for acute leukemia. HemaSphere. 2024;8:e70026.","journal-title":"HemaSphere"},{"key":"2991_CR52","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3324\/haematol.2016.148510","volume":"102","author":"F Baron","year":"2017","unstructured":"Baron F, Mohty M, Blaise D, Soci\u00e9 G, Labopin M, Esteve J, et al. Anti-thymocyte globulin as graft-versus-host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102:224\u201334.","journal-title":"Haematologica"},{"key":"2991_CR53","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1056\/NEJMoa1506002","volume":"374","author":"N Kr\u00f6ger","year":"2016","unstructured":"Kr\u00f6ger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, et al. Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med. 2016;374:43\u201353.","journal-title":"N Engl J Med"},{"key":"2991_CR54","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1016\/S2352-3026(18)30022-X","volume":"5","author":"F Fasslrinner","year":"2018","unstructured":"Fasslrinner F, Schetelig J, Burchert A, Kramer M, Trenschel R, Hegenbart U, et al. Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial. Lancet Haematol. 2018;5:e161\u2013e169.","journal-title":"Lancet Haematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02991-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02991-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02991-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:02:13Z","timestamp":1791558133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-026-02991-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,17]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2991"],"URL":"https:\/\/doi.org\/10.1038\/s41409-026-02991-1","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,17]]},"assertion":[{"value":"21 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"There are no conflicts of interest to report.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}